S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
Log in
NASDAQ:TPTX

Turning Point Therapeutics Stock Forecast, Price & News

$105.19
-1.65 (-1.54 %)
(As of 12/3/2020 04:30 PM ET)
Add
Compare
Today's Range
$103.84
Now: $105.19
$110.00
50-Day Range
$92.19
MA: $105.70
$119.82
52-Week Range
$31.30
Now: $105.19
$122.85
Volume318,895 shs
Average Volume386,708 shs
Market Capitalization$5.07 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.3
Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and TPX-0131, a preclinical ALK inhibitor. The company was founded in 2013 and is headquartered in San Diego, California.

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.65 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TPTX
CUSIPN/A
CIKN/A
Phone858-926-5251
Employees109

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$11.28 per share

Profitability

Net Income$-72,130,000.00

Miscellaneous

Market Cap$5.07 billion
Next Earnings Date3/15/2021 (Estimated)
OptionableNot Optionable
$105.19
-1.65 (-1.54 %)
(As of 12/3/2020 04:30 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for TPTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Turning Point Therapeutics (NASDAQ:TPTX) Frequently Asked Questions

How has Turning Point Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Turning Point Therapeutics' stock was trading at $40.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TPTX stock has increased by 159.5% and is now trading at $105.19.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Turning Point Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Turning Point Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Turning Point Therapeutics?

Wall Street analysts have given Turning Point Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Turning Point Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Turning Point Therapeutics' next earnings date?

Turning Point Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for Turning Point Therapeutics
.

How were Turning Point Therapeutics' earnings last quarter?

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) issued its quarterly earnings results on Thursday, November, 12th. The company reported ($0.42) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.79) by $0.37.
View Turning Point Therapeutics' earnings history
.

What price target have analysts set for TPTX?

6 analysts have issued 1 year price targets for Turning Point Therapeutics' shares. Their forecasts range from $116.00 to $133.00. On average, they anticipate Turning Point Therapeutics' share price to reach $127.33 in the next year. This suggests a possible upside of 21.1% from the stock's current price.
View analysts' price targets for Turning Point Therapeutics
.

Are investors shorting Turning Point Therapeutics?

Turning Point Therapeutics saw a decrease in short interest during the month of October. As of October 30th, there was short interest totaling 2,780,000 shares, a decrease of 16.3% from the October 15th total of 3,320,000 shares. Based on an average daily trading volume, of 449,100 shares, the short-interest ratio is currently 6.2 days.
View Turning Point Therapeutics' Short Interest
.

Who are some of Turning Point Therapeutics' key competitors?

What other stocks do shareholders of Turning Point Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include NVIDIA (NVDA), Main Street Capital (MAIN), OPKO Health (OPK), The Boeing (BA), General Motors (GM), AbbVie (ABBV), Gilead Sciences (GILD), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ) and Livongo Health (LVGO).

Who are Turning Point Therapeutics' key executives?

Turning Point Therapeutics' management team includes the following people:
  • Dr. Athena Maria Countouriotis, Pres, CEO & Director (Age 48, Pay $985.01k)
  • Ms. Yi Larson, Exec. VP & CFO (Age 40, Pay $864.41k)
  • Dr. Mohammad Hirmand, Exec. VP & Chief Medical Officer (Age 50, Pay $424.25k)
  • Dr. Siegfried Reich, Exec. VP & Chief Scientific Officer (Age 60)
  • Mr. Brian L. Baker CPA, M.S., MS, CPA, Sr. VP of Fin. & Admin. (Age 53)
  • Mr. James S. Mazzola, Sr. VP of Corp. Communication & Investor Relations
  • Ms. Annette C. North, Exec. VP, Gen. Counsel & Company Sec. (Age 54)
  • Mr. Andrew John Partridge, Exec. VP & Chief Commercial Officer (Age 51)
  • Ms. Heather Adams, VP of HR
  • Dr. Jeffrey P. Whitten, Sr. VP of Pre-Clinical Devel.

When did Turning Point Therapeutics IPO?

(TPTX) raised $167 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 9,300,000 shares at $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Turning Point Therapeutics' stock symbol?

Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."

Who are Turning Point Therapeutics' major shareholders?

Turning Point Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.70%), State Street Corp (2.69%), Lord Abbett & CO. LLC (1.78%), Federated Hermes Inc. (1.33%), Jennison Associates LLC (1.33%) and Wells Fargo & Company MN (1.29%). Company insiders that own Turning Point Therapeutics stock include Athena Countouriotis, Brian Lee Baker, Carl L Gordon, Cormorant Asset Management, Lp, Jingrong Jean Cui, Simeon George and Yi Larson.
View institutional ownership trends for Turning Point Therapeutics
.

Which institutional investors are selling Turning Point Therapeutics stock?

TPTX stock was sold by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, AXA S.A., Castleark Management LLC, Advisory Research Inc., Morgan Stanley, Candriam Luxembourg S.C.A., Jennison Associates LLC, and Mackay Shields LLC.
View insider buying and selling activity for Turning Point Therapeutics
.

Which institutional investors are buying Turning Point Therapeutics stock?

TPTX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Massachusetts Financial Services Co. MA, Wells Fargo & Company MN, Peregrine Capital Management LLC, Emerald Mutual Fund Advisers Trust, Charles Schwab Investment Management Inc., and Emerald Advisers LLC. Company insiders that have bought Turning Point Therapeutics stock in the last two years include Athena Countouriotis, Brian Lee Baker, Carl L Gordon, Cormorant Asset Management, Lp, Simeon George, and Yi Larson.
View insider buying and selling activity for Turning Point Therapeutics
.

How do I buy shares of Turning Point Therapeutics?

Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Turning Point Therapeutics' stock price today?

One share of TPTX stock can currently be purchased for approximately $105.19.

How big of a company is Turning Point Therapeutics?

Turning Point Therapeutics has a market capitalization of $5.07 billion. The company earns $-72,130,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Turning Point Therapeutics employs 109 workers across the globe.

What is Turning Point Therapeutics' official website?

The official website for Turning Point Therapeutics is www.tptherapeutics.com.

How can I contact Turning Point Therapeutics?

Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at 858-926-5251 or via email at [email protected]

This page was last updated on 12/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.